For the first-of-its-kind, we disclose a new alternative and improved synthesis of an anti-coagulant drug rivaroxaban with their insilico studies, physicochemical and ADMET properties. We developed the synthesis with an overall yield of 24%, and diminished reaction times. An alternative and inexpensive chemical urea, which formed oxalidinone ring in a cost-efficient method have been developed. Here, the drug was docked with protein targets (PDB: 2Q3G, 3CEN, and 4CRC) as anti-coagulant agent. Docking results along with physicochemical and pharmacokinetic properties have been evaluated and compared with commercially available drugs such as apixaban, dabigatran, and warfarin. All these analysisprovides insight into anti-coagulant properties of rivaroxabanand provide researchers to design and develop anti-coagulant therapeutic drugs. This synthetic protocol offers an economic, cost-effective, eco-friendly, high yielding, non-tedious, by-product-free, and impurity-free synthesis of rivaroxaban which enables direct isolation of API.